Anastasios Raptis

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 253 citations · Full text

Medicine, Oncology, Pharmacology +12

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Fredrik Schjesvold, Albert Oriol, Lionel Karlin et al. · The Lancet Haematology · 2019 · 242 citations · Full text

Medicine, Oncology, Pharmacology +11

Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units

Jeffrey J. Molldrem, Emmanuel Clave, Yin Jiang et al. · Blood · 1997 · 235 citations · Full text

Life Sciences, Hematology, Immunology +14

Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia

Michael Boyiadzis, Mounzer Agha, Robert L. Redner et al. · Cytotherapy · 2017 · 179 citations

Life Sciences, Immunology, Oncology +17

Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Kenneth A. Foon, Michael Boyiadzis, Stephanie R. Land et al. · Journal of Clinical Oncology · 2008 · 176 citations · Full text

Medicine, Oncology, Pharmacotherapy +12